Annual Review 2014
Annual Review 2014

Programs in Clinical Trial
or Registration

We prioritize our R&D efforts in areas with the greatest scientific and commercial promise: immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, rare diseases, and biosimilars. Through major research efforts across multiple modalities — including small molecules, biologics and vaccines — Pfizer is researching and developing unique therapies that will matter most to the people we serve.

As of February 27, 2015

View the latest pipeline on

Q: How does Pfizer choose what medicines to focus R&D efforts on?
Julie Schiffman
Portfolio & Decision Analysis